tiprankstipranks
Trending News
More News >
So-Young International Inc (SY)
NASDAQ:SY
US Market

So-Young International (SY) AI Stock Analysis

Compare
135 Followers

Top Page

SY

So-Young International

(NASDAQ:SY)

47Neutral
So-Young International's stock score is negatively impacted by weak financial performance, characterized by declining revenues and significant net losses. The technical analysis supports a weak momentum, and the valuation is unattractive due to a negative P/E ratio and lack of dividends. However, the earnings call highlights growth in aesthetic services and strong customer satisfaction, which may provide a path for recovery if the company can manage its costs and leverage its cash position effectively.

So-Young International (SY) vs. S&P 500 (SPY)

So-Young International Business Overview & Revenue Model

Company DescriptionSo-Young International (SY) is a leading online platform in China, primarily focused on the medical aesthetics and healthcare sectors. The company offers a comprehensive suite of services, which includes providing consumers with access to information relating to medical aesthetic procedures, connecting them with service providers, and facilitating reservations and transactions. Additionally, So-Young supports healthcare professionals and organizations by offering marketing and customer management tools to enhance their reach and operational efficiency.
How the Company Makes MoneySo-Young International generates revenue through a multi-faceted business model primarily driven by service fees and commissions. The company earns service fees from medical aesthetic service providers who use its platform to reach potential clients. Additionally, So-Young takes a commission from transactions facilitated through its platform when consumers book aesthetic procedures. The company also monetizes its user base by offering marketing and advertising solutions to healthcare professionals and organizations looking to promote their services. Key partnerships with clinics, hospitals, and other medical institutions further bolster its revenue streams by expanding the range of services available on its platform, thus attracting more users and driving greater transaction volumes.

So-Young International Financial Statement Overview

Summary
So-Young International shows potential with notable revenue growth and strong gross margin. However, challenges remain in converting revenue into net profit and generating positive free cash flow. The balance sheet is a strong point with a solid equity base and low leverage, indicating stability. The company needs to focus on improving operational efficiency and cash flow management to enhance its overall financial health.
Income Statement
55
Neutral
The company exhibits a mixed performance in its income statement. The gross profit margin for the latest year is approximately 63.7%, indicating strong profitability in core operations. However, the net profit margin is about 1.4%, revealing challenges in controlling overall expenses. Revenue grew by 19% from the previous year, which is a positive sign of growth. EBIT and EBITDA margins are negative, indicating potential operational inefficiencies.
Balance Sheet
70
Positive
The balance sheet shows a healthy equity ratio of 76%, reflecting a solid financial position with considerable equity backing. The debt-to-equity ratio is low at approximately 0.06, suggesting limited leverage and financial risk. Return on equity is positive at 0.9%, although relatively modest, it marks an improvement from losses in prior years.
Cash Flow
40
Negative
Cash flow analysis indicates challenges, with a negative free cash flow of approximately -28.7 million, though an improvement from the previous year's deeper negative value. Operating cash flow to net income ratio is around 1.06, suggesting that operational cash generation is in line with net income. However, free cash flow to net income ratio is negative, highlighting issues in cash retention after capital expenditures.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
1.50B1.50B1.26B1.69B1.29B1.15B
Gross Profit
948.92M953.69M864.58M1.36B1.08B953.01M
EBIT
-37.01M-61.05M-102.81M82.79M-56.69M145.18M
EBITDA
-2.19M-14.96M-55.72M63.39M-42.61M151.30M
Net Income Common Stockholders
33.51M21.28M-66.11M-37.64M5.81M176.72M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.32B1.33B1.57B1.74B2.65B2.83B
Total Assets
3.19B3.21B3.20B3.33B3.29B3.23B
Total Debt
151.75M145.77M71.26M105.89M132.51M158.60M
Net Debt
-296.28M-280.35M-623.16M-1.23B-994.54M-726.07M
Total Liabilities
664.63M653.25M590.00M813.33M672.44M587.32M
Stockholders Equity
2.41B2.44B2.50B2.45B2.60B2.64B
Cash FlowFree Cash Flow
0.00-28.68M-128.58M39.23M142.22M346.28M
Operating Cash Flow
0.0022.50M-112.87M84.29M179.18M383.82M
Investing Cash Flow
0.00-202.61M-572.21M339.82M123.84M-1.34B
Financing Cash Flow
0.00-100.02M-13.59M-216.74M-5.80M1.27B

So-Young International Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.71
Price Trends
50DMA
0.91
Negative
100DMA
0.88
Negative
200DMA
0.91
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
44.69
Neutral
STOCH
15.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SY, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.89, below the 50-day MA of 0.91, and below the 200-day MA of 0.91, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.69 is Neutral, neither overbought nor oversold. The STOCH value of 15.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SY.

So-Young International Risk Analysis

So-Young International disclosed 86 risk factors in its most recent earnings report. So-Young International reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

So-Young International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$79.35M11.114.68%-0.83%-38.41%
58
Neutral
$67.13M292.520.36%-10.82%
48
Neutral
$6.36B1.24-44.94%2.70%18.33%1.47%
SYSY
47
Neutral
$72.15M17.80-27.49%-3.53%-2848.11%
43
Neutral
$89.56M
-93.33%
VOVOR
34
Underperform
$72.16M-94.52%2.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SY
So-Young International
0.77
-0.37
-32.46%
FONR
Fonar
12.36
-5.28
-29.93%
PETS
Petmed Express
3.13
-1.01
-24.40%
PAVS
Paranovus Entertainment Technology
1.34
-0.09
-6.29%
VOR
Vor Biopharma
0.62
-1.42
-69.61%

So-Young International Earnings Call Summary

Earnings Call Date: Mar 28, 2025 | % Change Since: -25.26% | Next Earnings Date: May 26, 2025
Earnings Call Sentiment Neutral
The earnings call reveals significant growth in the aesthetic center business and strong customer satisfaction, indicating positive operational progress. However, the financials are negatively impacted by a substantial goodwill impairment and a decline in revenue from So-Young Prime, leading to an overall net loss. The robust cash position provides a positive foundation for future growth, but increased operating expenses remain a concern.
Highlights
Aesthetic Center Business Growth
Revenue from the aesthetic center business surged to RMB81.3 million during the quarter, up 79% quarter-over-quarter and 702% year-over-year, with 38,000 verified paid visits and over 81,500 verified paid aesthetic treatments.
Expansion of So-Young Clinics
In Q4, 19 So-Young Clinics were opened across nine core cities, with 11 clinics achieving positive monthly operating cash flow in December, indicating strong urban presence and operational success.
Strong Customer Satisfaction
Customer satisfaction remains at an industry-leading 4.98 out of 5, reflecting high quality service delivery and positive customer experience.
Robust Cash Position
Maintained a robust cash position with cash and cash equivalents, restricted cash, and term deposits totaling RMB1.25 billion as of December 31, 2024.
Lowlights
Net Loss Due to Goodwill Impairment
Net loss attributable to So-Young was RMB607.6 million, primarily driven by a onetime goodwill impairment charge of RMB540 million for the subsidiary, Wuhan Miracle.
Decrease in Revenue from So-Young Prime
Total revenues during the quarter were RMB369.2 million, down 5.5% year-over-year, primarily due to a decrease in revenue generated by So-Young Prime.
Increased Operating Expenses
Total operating expenses were RMB815.2 million, up 216.2% year-over-year, significantly impacting profitability.
Decline in Sales of Medical Products
Sales of medical products and maintenance services were RMB86.2 million, down 15.2% year-over-year, primarily due to a decrease in order volume for medical equipment.
Company Guidance
During the fourth quarter of 2024, So-Young reported total revenue of RMB369.2 million, with a net loss attributable to the company amounting to RMB607.6 million. The non-GAAP net loss was RMB53.2 million, significantly impacted by a onetime goodwill impairment charge of RMB540 million related to their subsidiary, Wuhan Miracle. The company continued its vertical integration strategy, resulting in a 79% quarter-over-quarter and 702% year-over-year increase in revenue from its aesthetic center business, reaching RMB81.3 million. So-Young opened 19 new clinics across nine core cities, achieving positive monthly operating cash flow in 11 centers by December. They reported over 38,000 verified paid visits and more than 81,500 verified paid aesthetic treatments. The customer satisfaction score was an industry-leading 4.98 out of 5. For the first quarter of 2025, So-Young projected total revenues between RMB280 million and RMB300 million, expecting steady financial improvements with ongoing expansion and market stabilization.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.